Account
Inquiry
Tirzepatide 10mg (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for metabolic research applications. This compound demonstrates superior efficacy in glucose regulation and weight management studies compared to selective GLP-1 receptor agonists.
The tirzepatide 10mg formulation exhibits greater affinity for GIP receptors while maintaining significant activity at GLP-1 receptors. This unique dual mechanism has shown promising results in preclinical studies for metabolic regulation and weight management applications.
Our tirzepatide 10mg is supplied as a lyophilized white powder with trifluoroacetic acid (TFA) completely removed for research safety. The product undergoes rigorous quality control testing to ensure consistent purity and performance in laboratory settings.
Key research applications include: metabolic syndrome studies, glucose regulation research, weight management investigations, and comparative pharmacology studies with other incretin-based compounds.
Customization options available for research institutions include: vial size customization, cap color differentiation, bulk packaging solutions, and specific purity requirements. Fresh production batches are available every 6-8 days to ensure optimal stability and performance.
Important Note: This product is intended for research purposes only. Not for human consumption or diagnostic use. Proper laboratory handling procedures should be followed at all times.
